News
Investors in the region are awaiting India's HSBC Composite flash purchasing managers' index reading for August expected ...
Zacks.com on MSN1d
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...
Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...
Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...
Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell ...
DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the ...
Developed by Daiichi Sankyo and Merck, it treats patients with Pretreated Extensive-Stage Small Cell Lung Cancer.
US FDA grants breakthrough therapy designation to Daiichi Sankyo & Merck’s ifinatamab deruxtecan for patients with pretreated extensivestage SCLC: Tokyo Tuesday, August 19, 2025 ...
Zacks.com on MSN1d
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback